Wall Street analysts predict that Celldex Therapeutics, Inc. (NASDAQ:CLDX) will post earnings per share of ($0.17) for the current quarter, Zacks reports. Two analysts have provided estimates for Celldex Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.21) and the highest estimate coming in at ($0.11). Celldex Therapeutics reported earnings per share of ($0.28) during the same quarter last year, which suggests a positive year-over-year growth rate of 39.3%. The firm is expected to report its next earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Celldex Therapeutics will report full year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($0.96) to ($0.55). For the next financial year, analysts forecast that the business will report earnings of ($0.71) per share, with EPS estimates ranging from ($1.07) to ($0.20). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Celldex Therapeutics.
Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.08. The business had revenue of $3.50 million during the quarter, compared to the consensus estimate of $1.49 million. Celldex Therapeutics had a negative net margin of 730.06% and a negative return on equity of 44.64%. The company’s revenue for the quarter was up 87.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.30) EPS.
A number of analysts have weighed in on CLDX shares. BidaskClub downgraded shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Cantor Fitzgerald reissued a “buy” rating and set a $9.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, March 7th. HC Wainwright set a $10.00 target price on shares of Celldex Therapeutics and gave the company a “buy” rating in a research report on Friday, February 9th. Finally, Leerink Swann reissued a “market perform” rating and set a $3.00 target price (down previously from $4.00) on shares of Celldex Therapeutics in a research report on Thursday, March 8th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $6.38.
NASDAQ:CLDX opened at $1.99 on Thursday. The company has a market cap of $280.74, a price-to-earnings ratio of -2.49 and a beta of 2.45. Celldex Therapeutics has a fifty-two week low of $1.98 and a fifty-two week high of $3.41.
Several institutional investors have recently bought and sold shares of CLDX. Millennium Management LLC boosted its holdings in shares of Celldex Therapeutics by 21.8% during the 4th quarter. Millennium Management LLC now owns 2,241,521 shares of the biopharmaceutical company’s stock worth $6,366,000 after buying an additional 400,965 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Celldex Therapeutics by 741.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 352,511 shares of the biopharmaceutical company’s stock worth $1,008,000 after buying an additional 310,638 shares in the last quarter. Two Sigma Investments LP bought a new position in shares of Celldex Therapeutics during the 4th quarter worth approximately $800,000. BlackRock Inc. boosted its holdings in shares of Celldex Therapeutics by 2.9% during the 4th quarter. BlackRock Inc. now owns 9,930,701 shares of the biopharmaceutical company’s stock worth $28,203,000 after buying an additional 279,287 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its holdings in shares of Celldex Therapeutics by 72.3% during the 4th quarter. TIAA CREF Investment Management LLC now owns 651,531 shares of the biopharmaceutical company’s stock worth $1,850,000 after buying an additional 273,433 shares in the last quarter. Hedge funds and other institutional investors own 55.49% of the company’s stock.
WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/celldex-therapeutics-inc-cldx-expected-to-announce-earnings-of-0-17-per-share.html.
About Celldex Therapeutics
Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.
Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.